ESMO 2024: Anlotinib and penpulimab gather attention in HCC with APOLLO results
Advanced hepatocellular carcinoma (aHCC) has a dire prognostic outlook, with an 18.4% five-year survival rate in non-metastatic and a 2% survival in metastatic disease. At the European Society of Medical Oncology (ESMO) Congress 2024, the results of the …